Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Vaxart Inc
NB11Current price
0.58 EUR
+0.0055 EUR (+0.96%)
Last closed
0.72 USD
Company
vaxart.com
ISIN
US92243A2006
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
155 909 440 USD
Yield for 12 month
-25.88 %
1Y
3Y
5Y
10Y
15Y
NB11
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California. Address: 170 Harbor Way, South San Francisco, CA, United States, 94080
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
4.83 USDP/E ratio
–Dividend Yield
–Current Year
+7 379 000 USD
Last Year
+107 000 USD
Current Quarter
+6 401 000 USD
Last Quarter
+2 181 000 USD
Current Year
+2 879 000 USD
Last Year
-3 160 000 USD
Current Quarter
+5 301 000 USD
Last Quarter
+1 081 000 USD
Key Figures NB11
1 year
3 years
5 years
10 years
EBITDA
-66 262 000 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-39.68 %
PEG Ratio
–
Return On Equity TTM
-91.66 %
Wall Street Target Price
4.83 USD
Revenue TTM
13 928 000 USD
Book Value
0.35 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
371.4 %
Dividend Yield
–
Gross Profit TTM
-80 947 000 USD
Earnings per share
-0.45 USD
Diluted Eps TTM
-0.45 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics NB11
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History NB11
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
09.11.2012
Forward Annual Dividend Yield
–
Last Split Factor
1:11
Payout Ratio
–
Last Split Date
14.02.2018
Dividend Date
14.02.2018
Stock Valuation NB11
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
42.735
Enterprise Value Revenue
7.1661
Price Sales TTM
11.194
Enterprise Value EBITDA
-0.1715
Price Book MRQ
1.9485
Financials NB11
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators NB11
For 52 weeks
0.52 USD
1.54 USD
50 Day MA
0.82 USD
Shares Short Prior Month
12 071 690
200 Day MA
0.88 USD
Short Ratio
9.45
Shares Short
11 726 171
Short Percent
5.2 %
BeatStart